Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS (AchALS)
Primary Purpose
Amyotrophic Lateral Sclerosis
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
endocannabinoid palmitoylethanolamide (PEA)
Riluzole
Sponsored by
About this trial
This is an interventional basic science trial for Amyotrophic Lateral Sclerosis
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of ALS according to the El-Escorial criteria;
- Age> 18 years;
- ALS Functional Rating Scale-Revised (ALSFRS- r) score> 20;
- Forced Vital Capacity (FVC)> 30%;
- Treatment with Riluzole.
Exclusion Criteria:
- Other diseases motor neurons;
- Experimental treatments in the previous three months;
- Pregnant or breast-feeding;
- Contraindications to the use of riluzole;
- Patients undergoing tracheostomy, enteral or parenteral supply;
- Severe psychiatric disorders.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Riluzole
PEA plus Riluzole
Arm Description
Riluzole 50 mg twice daily in ALS patients
Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
Outcomes
Primary Outcome Measures
Changes from baseline in pulmonary capacity of ALS patients at 6 months.
Changes of the percentage of predicted forced vital capacity (FVC %) will be measured
Secondary Outcome Measures
Changes in acetylcholine receptors (AChR) currents and Analysis of the composition of AChRs subunits in ALS muscles.
Utilization of voltage-clamp intracellular recordings in oocytes transplanted with membranes from ALS muscles.
Changes from baseline in muscle strength of ALS patients at 6 months.
Changes of the Medical Research Council (MRC) scale score will be measured
Changes from baseline in electrophysiological parameters of ALS patients at 6 months
Changes of the compound muscle action potential (CMAP) amplitude of ulnar and phrenic nerves will be measured
Full Information
NCT ID
NCT02645461
First Posted
December 22, 2015
Last Updated
January 1, 2016
Sponsor
University of Roma La Sapienza
1. Study Identification
Unique Protocol Identification Number
NCT02645461
Brief Title
Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS
Acronym
AchALS
Official Title
Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Roma La Sapienza
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Amyotrophic lateral sclerosis (ALS) is a fatal disease leading to motor neuron degeneration and progressive paralysis. Other studies have revealed defects in skeletal muscle even in absence of motor neuron anomalies, focusing on acetylcholine receptors (AChRs) and supporting the so-called "dying-back" hypothesis. Outcome of this study will be to understand if the endocannabinoid palmitoylethanolamide (PEA) can reduce the rundown of AChRs currents in ALS muscle, and if it can modify ALS patients' clinical and electrophysiological parameters.
Detailed Description
Outcome:
Monitoring the efficacy and safety of PEA in the treatment of patients with ALS. Analysis of AChR currents and description of the composition of AChRs subunits in ALS muscles
Design of the Study:
A randomized controlled blinded study. Patients with sporadic ALS will receive riluzole alone or riluzole+PEA in order to investigate the clinical and electrophysiological effects of treatment. The expected number of enrolled patients will be 50.
All patients satisfying the selection criteria will be randomized into two groups: a first group will be treated only with riluzole, the second group with riluzole associated with PEA (Normast 600 mg microgranular, 2 sachets/day). The randomization will be done stratifying patietns according to type of clinical onset (bulbar vs. spinal). The patients will be enrolled in the Department of Neurology and Psychiatry, University of Rome "Sapienza".
The visits will be performed at 0 (randomization), 3 and 6 months. At each visit the ALS Functional Rating Scale-Revised (ALSFRS-R), the percentage of predicted forced vital capacity (FVC%), the Medical Research Council (MRC) score for muscle strength limited to the right upper limbs, and the compound muscle action potentials (CMAP) from right ulnar and phrenic nerves will be assessed. A muscle biopsy will be done at the end of the study. The obtained results will be compared with those observed in muscle samples from denervated (non-ALS) control patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amyotrophic Lateral Sclerosis
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Riluzole
Arm Type
Active Comparator
Arm Description
Riluzole 50 mg twice daily in ALS patients
Arm Title
PEA plus Riluzole
Arm Type
Experimental
Arm Description
Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
Intervention Type
Drug
Intervention Name(s)
endocannabinoid palmitoylethanolamide (PEA)
Other Intervention Name(s)
PEA
Intervention Description
Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
Intervention Type
Drug
Intervention Name(s)
Riluzole
Intervention Description
Riluzole 50 mg twice daily
Primary Outcome Measure Information:
Title
Changes from baseline in pulmonary capacity of ALS patients at 6 months.
Description
Changes of the percentage of predicted forced vital capacity (FVC %) will be measured
Time Frame
six months
Secondary Outcome Measure Information:
Title
Changes in acetylcholine receptors (AChR) currents and Analysis of the composition of AChRs subunits in ALS muscles.
Description
Utilization of voltage-clamp intracellular recordings in oocytes transplanted with membranes from ALS muscles.
Time Frame
six months
Title
Changes from baseline in muscle strength of ALS patients at 6 months.
Description
Changes of the Medical Research Council (MRC) scale score will be measured
Time Frame
six months
Title
Changes from baseline in electrophysiological parameters of ALS patients at 6 months
Description
Changes of the compound muscle action potential (CMAP) amplitude of ulnar and phrenic nerves will be measured
Time Frame
six months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of ALS according to the El-Escorial criteria;
Age> 18 years;
ALS Functional Rating Scale-Revised (ALSFRS- r) score> 20;
Forced Vital Capacity (FVC)> 30%;
Treatment with Riluzole.
Exclusion Criteria:
Other diseases motor neurons;
Experimental treatments in the previous three months;
Pregnant or breast-feeding;
Contraindications to the use of riluzole;
Patients undergoing tracheostomy, enteral or parenteral supply;
Severe psychiatric disorders.
12. IPD Sharing Statement
Learn more about this trial
Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS
We'll reach out to this number within 24 hrs